New Price for Muscular Dystrophy Drug Draws Criticism - NBC Bay Area
National & International News
The day’s top national and international news

New Price for Muscular Dystrophy Drug Draws Criticism

In the spotlight is a steroid called deflazacort

    processing...

    NEWSLETTERS

    12 Ways to Effortlessly Surprise Your Friends and Co-Workers
    NBC 5 News

    Christine McSherry is used to a fight. Her son, Jett, was diagnosed with Duchenne muscular dystrophy, a rare, debilitating condition, when he was 5. He lost the ability to walk just before he turned 14.

    McSherry has become an outspoken advocate for Jett and other kids with Duchenne, particularly in fighting for access to drugs she's convinced help against the disease's devastating effects, CNBC reported.

    Jett, now 21, has been taking a steroid called deflazacort since he was 8. Deflazacort wasn't approved in the U.S., so McSherry and a number of other families of kids with Duchenne imported the drug from overseas. She says it cost about $1,200 a year out of pocket.

    On Monday, deflazacort got a new price tag: $35,000 a year for a patient in the U.S. weighing 25 kilograms, or about 55 pounds.

    How to Step Up Your Coffee Game With a Chemex

    [NATL] How to Step Up Your Coffee Game With a Chemex

    Making delicious home-brewed coffee will be easier than you think with these quick and easy steps to make coffee using a chemex. 

    (Published Thursday, Dec. 14, 2017)

    PTC Therapeutics, which set the price, says it "represents sustainable pricing which balances providing access to eligible patients in the United States…while maintaining sufficient infrastructure and programs including continued investment in Duchenne."